Table 2 Clinical characteristics and embryo development of all patients in SERa + and SERa– cycles
Characteristic | SERa + cycles (n = 545) | SERa- cycles (n = 545) | t/χ2/z | P-value |
|---|---|---|---|---|
Age, y | 33.90 ± 5.14 | 33.97 ± 5.63 | -0.208 | 0.835 |
BMI, kg/m2 | 22.10 ± 3.11 | 22.13 ± 3.12 | -0.152 | 0.879 |
Years infertile, y | 5.62 ± 3.92 | 5.72 ± 4.23 | -0.405 | 0.686 |
Type of infertility | 0.381 | 0.537 | ||
Primary infertility | 49.20 (320/545) | 50.80 (330/545) | ||
Secondary infertility | 51.10 (225/545) | 48.90 (215/545) | ||
Basal FSH, IU/L | 8.15 ± 3.53 | 8.17 ± 3.50 | 0.923 | |
Protocol, % | 11.340 | 0.003 | ||
Agonist | 58.00 (316/545) | 60.60(330/545) | ||
Antagonist | 27.20 (148/545) | 31.00 (169/545) | ||
Others | 14.90 (84/545) | 8.40 (46/545) | ||
Total dose of Gn, IU | 2199.13 ± 928.94 | 2071.28 ± 880.37 | 2.324 | 0.020 |
Initial dose of Gn, IU | 192.82 ± 67.01 | 188.96 ± 63.86 | 0.970 | 0.332 |
Duration of Gn, days | 10.68 ± 2.60 | 10.35 ± 2.94 | 1.956 | 0.051 |
No. of oocytes retrieved, n | 12.30 ± 7.19 | 9.89 ± 7.14 | 0.873 | < 0.001 |
No. of SERa- oocytes, n | 9.16 ± 7.12 | 9.89 ± 7.14 | -1.690 | 0.091 |
Serum oestradiol concentration, ng/L | 2822.27 ± 1501.84 | 2434.00 ± 1523.53 | 0.853 | < 0.001 |
Serum progesterone concentration, ug/L | 0.95 (0.66–1.31) | 0.94 (0.64–1.33) | -0.093 | 0.926 |
Endometrial thickness, mm | 11.25 ± 2.93 | 11.14 ± 3.08 | 0.457 | 0.539 |
2PN fertilization rate, % | 58.73 ± 21.74 | 58.39 ± 29.06 | 0.240 | 0.811 |
Poly-pronucleus zygote rate, % | 0.00 (0.00–0.00) | 0.00 (0.00–0.00) | -1.663 | 0.102 |
Cleavage rate from 2PN zygote, % | 88.52 ± 21.68 | 86.79 ± 26.74 | 1.171 | 0.242 |
Good-quality embryo rate, % | 24.20(1,110/3,581) | 28.30(828/2,925) | 15.451 | < 0.001 |
No. of available embryo, n | 3.64 ± 2.43 | 3.15 ± 2.32 | 3.396 | 0.001 |
Blastocyst formation rate, % | 47.27 ± 33.76 | 46.77 ± 35.48 | 0.185 | 0.853 |
Cancellation rate, % | 31.70 (173/545) | 34.10 (186/545) | 0.702 | 0.402 |